Daily step count is associated with plasma c-reactive protein and il-6 in a us cohort with COPD

Chest

Volumn 145, Issue 3, 2014, Pages 542-550

  Moy, Marilyn L ^a,b,c,d   Teylan, Merilee ^a,b   Weston, Nicole A ^a,b   Gagnon, David R ^d   Danilack, Valery A ^a,b,e   Garshick, Eric ^a,b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ACCELEROMETER; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DAILY STEP COUNT; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEASONAL VARIATION; SMOKING; UNITED STATES; WALKING;

ACCELEROMETRY; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MOTOR ACTIVITY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; WALKING;

EID: 84896734732     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1052     Document Type: Article

References (48)

1. Mannino DM, Buist AS.Global burden of COPD: risk factors, prevalence, and futuretrends.Lancet.2007; 370 (9589):765-773
2. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive LungDisease.Global strategy for the diagnosis, management, and prevention of chronicobstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med.2007; 176 (6):532-555
3. Moy ML, Matthess K, Stolzmann K, Reilly J, Garshick E.Free-living physical activity inCOPD: assessment with accelerometer and activity checklist.J Rehabil Res Dev.2009;46 (2):277-286
4. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R.Characteristicsof physical activities in daily life in chronic obstructive pulmonary disease.Am J Respir Crit Care Med.2005; 171 (9):972-977
5. Watz H, Waschki B, Meyer T, Magnussen H.Physical activity in patients with COPD. Eur Respir J.2009; 33 (2):262-272
6. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM.Regular physicalactivity reduces hospital admission and mortalityin chronic obstructive pulmonarydisease: a population based cohort study.Thorax.2006; 61 (9):772-778
7. Garcia-Rio F, Rojo B, Casitas R, et al.Prognostic value of the objectivemeasurement of daily physical activity in patients with COPD.Chest.2012; 142 (2) :338-346
8. Moy ML, Danilack VA, Weston NA, Garshick E.Daily step counts in a US cohort withCOPD.Respir Med.2012; 106 (7):962-969
9. Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR. A pilot study of anInternet walking program and pedometer in COPD.Respir Med.2012; 106 (9):1342 -1350
10. Depew ZS, Novotny PJ, Benzo RP.How many steps are enough to avoid severephysical inactivity in patients with chronic obstructive pulmonary disease? Respirology.2012; 17 (6):1026-1027
11. Moy ML, Teylan M, Weston NA, Gagnon DR, Garshick E.Daily step count predictsacute exacerbations in a US cohort with COPD.PLoS ONE.2013; 8 (4):e60400
12. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study.Chest.2011; 140(2): 331-342
13. Gan WQ, Man SFP, Senthilselvan A, Sin DD.Association between chronicobstructive pulmonary disease and systemic infl ammation: a systematic review and ameta-analysis.Thorax.2004; 59 (7):574-580
14. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluationof COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators.COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.RespirRes.2011; 12:146
15. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD Longitudinally toIdentify Predictive Surrogate Endpoints (ECLIPSE) Investigators.Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.PLoSONE.2012; 7 (5):e37483
16. Kostikas K, Bakakos P, Papiris S, Stolz D, Celli BR. Systemic biomarkers in theevaluation and management of COPD patients: are we getting closer to clinicalapplication? Curr Drug Targets.2013; 14 (2):177-191
17. Perera WR, Hurst JR, Wilkinson TMA, et al.Infl amatory changes, recovery andrecurrence at COPD exacerbation. Eur Respir J.2007; 29 (3):527-534
18. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al.C-reactive protein levelsand clinically important predictive outcomes in stable COPD patients.Eur Respir J.2006; 27 (5):902-907
19. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG.C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med.2007; 175 (3):250-255
20. Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD.C-reactiveprotein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax.2006; 61 (10):849-853
21. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: across-sectional study.Am J Respir Crit Care Med.2008; 177 (7):743-751
22. Garcia-Rio F, Lores V, Mediano O, et al.Daily physical activity in patients withchronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation.Am J Respir Crit Care Med.2009; 180 (6):506-512
23. Garcia-Aymerich J, Serra I, Gómez FP, et al; Phenotype and Course of COPDStudy Group.Physical activity and clinical and functional status in COPD.Chest.2009;136 (1):62-70
24. Bolton CE, Broekhuizen R, Ionescu AA, et al.Cellular protein breakdown andsystemic infl ammation are unaffected by pul monary rehabilitation in COPD.Thorax.2007; 62 (2) :109-114
25. Vogiatzis I, Stratakos G, Simoes DCM, et al. Effects of rehabilitative exercise onperipheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax.2007; 62 (11):950-956
26. Rabinovich RA, Figueras M, Ardite E, et al.Increased tumour necrosis factor-aplasma levels during moderateintensity exercise in COPD patients.Eur Respir J.2003;21 (5): 789-794
27. Sewell L, Singh SJ, Williams JEA, Morgan MD.Seasonal variations affect physicalactivity and pulmonary rehabilitation outcomes.J Cardiopulm Rehabil Prev.2010; 30 (5):329-333
28. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R.Quantifyingphysical activity in daily life with questionnaires and motion sensors in COPD.Eur RespirJ.2006; 27 (5):1040-1055
29. Lichtman SW, Pisarska K, Berman ER, et al.Discrepancy between self-reportedand actual caloric intake and exercise in obese subjects.N Engl J Med.1992; 327 (27): 1893-1898
30. Albert RK, Connett J, Bailey WC, et al COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med.2011; 365 (8) :689-698
31. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force.Standardisation ofspirometry.Eur Respir J.2005; 26 (2):319-338
32. ATS Committee on Proficiency Standards for Clinical Pulmonary FunctionLaboratories.ATS statement: guidelines for the six-minute walk test.Am J Respir CritCare Med.2002; 166 (1):111-117
33. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure ofhealth status for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis.1992; 145 (6):1321-1327
34. Mahler DA, Wells CK.Evaluation of clinical methods for rating dyspnea.Chest.1988; 93 (3):580-586
35. Matthews CE, Hagströmer M, Pober DM, Bowles HR.Best practices for usingphysical activity monitors in populationbased research.Med Sci Sports Exerc.2012; 44 (1) (suppl 1) :S68-S76
36. Hankinson JL, Odencrantz JR, Fedan KB.Spirometric reference values from asample of the general US population.Am J Respir Crit Care Med.1999; 159 (1):179 -187
37. Celli BR, Locantore N, Yates J, et al; ECLIPSE Investigators.Infl ammatorybiomarkers improve clinical prediction of mortality in chronic obstructive pulmonarydisease.Am J Respir Crit Care Med.2012; 185 (10):1065-1072
38. Polkey MI, Spruit MA, Edwards LD, et al; ECLIPSE Investigators Six-minute-walk testin COPD: minimally clinically important difference for death or hospitalization.Am JRespir Crit Care Med.2013; 187 (4):382-386
39. Mora S, Cook N, Buring JE, Ridker PM, Lee IM.Physical activity and reduced risk ofcardiovascular events: potential mediating mechanisms. Circulation.2007; 116 (19):2110-2118
40. Hamer M, Stamatakis E.Physical activity and risk of cardiovascular disease events:infl ammatory and metabolic mechanisms.Med Sci Sports Exerc.2009; 41 (6):1206 -1211
41. Woods JA, Wilund KR, Martin SA, Kistler BM.Exercise, infl ammation and aging. Aging Dis.2012; 3 (1):130-140
42. Hamer M, Sabia S, Batty GD, et al. Physical activity and infl amatory markers over 10years: follow-up in men and women from the Whitehall II cohort study.Circulation.2012; 126 (8) :928-933
43. Clarenbach CF, Senn O, Sievi NA, et al.Determinants of endothelial function inpatients with COPD.Eur Respir J.2013; 42 (5):1194-1204
44. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG.Infl ammatorybiomarkers and comorbidities in chronic obstruc tive pulmonary disease.Am J RespirCrit Care Med.2012; 186 (10):982-988
45. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM.Absence ofdiurnal variation of C-reactive protein concentrations in healthy human subjects.ClinChem.2001; 47 (3):426-430
46. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP.IL-6 and itscircadian secretion in humans.Neuroimmunomodulation.2005; 12 (3):131-140
47. Walker PP, Burnett A, Flavahan PW, Calverley PMA. Lower limb activity and itsdeterminants in COPD.Thorax.2008; 63 (8):683-689
48. Rabinovich RA, Louvaris Z, Raste Y, et al; on behalf of the PROactive consortium.Validity of physical activity monitors during daily life in patients with COPD.Eur Respir J.2013; 42 (5):1205-1215